Web Date: October 30, 2017
Kymera launches with $30 million to tackle targeted protein degradation
Kymera Therapeutics has launched with $30 million in funding from Atlas Venture, Lilly Ventures, and Amgen Ventures. The firm will develop bifunctional small molecules that it believes can tackle disease-causing proteins that have long stymied drug developers.
Kymera is the latest biotech company working on targeted protein degradation, a way of tagging troublesome proteins for the cellular trash bin.
Traditionally, small molecule drugs . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society